Stock Markets May 5, 2026 09:48 AM

Ocugen Shares Drop After Discounted Convertible Note Sale Announced

Biotech company prices $115 million of convertible senior notes at 90% of par; shares tumble amid financing and mixed quarterly results

By Derek Hwang OCGN
Ocugen Shares Drop After Discounted Convertible Note Sale Announced
OCGN

Ocugen said it has privately priced $115 million of 6.75% convertible senior notes due 2034 at 90% of principal, prompting a roughly 17% decline in its stock. The offering, including a 13-day option for an additional $15 million, is expected to close on May 7, 2026, and is projected to generate about $99.5 million in net proceeds. The company will use roughly $32.7 million to repay an affiliate loan and the remainder for general corporate purposes. Separately, Ocugen reported first-quarter EPS of ($0.06) on revenue of $1.53 million.

Key Points

  • Ocugen priced $115 million of 6.75% convertible senior notes due 2034 at 90% of principal in a private offering, with a 13-day option for an additional $15 million.
  • Expected net proceeds are approximately $99.5 million, with about $32.7 million earmarked to repay a loan from affiliates of Avenue Capital Group and the rest for general corporate purposes.
  • The notes convert at 372.7866 shares per $1,000 principal (about $2.68 per share), a 45% premium to the $1.85 closing price on May 4, 2026; Ocugen reported Q1 EPS of ($0.06) on $1.53 million revenue.

Ocugen, Inc. announced a private placement of convertible senior notes that has coincided with a steep drop in its share price. The company said it priced $115 million of 6.75% Convertible Senior Notes due 2034 at 90% of the principal amount, and the news was followed by a roughly 17% decline in the stock on Tuesday.

The securities were sold to qualified institutional buyers. Ocugen also granted the initial purchaser a 13-day option to buy up to an additional $15 million of notes. The offering is expected to close on May 7, 2026, and after fees and expenses is anticipated to produce approximately $99.5 million in net proceeds.

Ocugen indicated it will allocate about $32.7 million of the proceeds to fully repay an outstanding loan owed to affiliates of Avenue Capital Group, including accrued interest and any prepayment fees. The company said the balance of the funds will be directed toward general corporate purposes.

The notes carry an annual interest rate of 6.75%, with interest payable semi-annually on May 15 and November 15, beginning November 15, 2026. The instruments mature on May 15, 2034. The initial conversion rate has been set at 372.7866 shares per $1,000 principal amount, which equates to a conversion price of approximately $2.68 per share. That conversion price represents a 45% premium to Ocugen's $1.85 closing price on May 4, 2026.

Terms of the notes include a non-redemption period during which Ocugen may not redeem the notes prior to May 15, 2029. Additionally, holders will have the right to require Ocugen to repurchase the notes on May 15, 2032, at 100% of the principal amount plus accrued interest.

In separate financial results, Ocugen reported first-quarter earnings per share of ($0.06), missing the analyst consensus of ($0.05) by $0.01. Revenue for the quarter was $1.53 million, which exceeded the consensus estimate of $501.4 thousand.

The planned note offering, its terms, and the mixed quarterly results together contributed to the market reaction. The company framed the financing as a combination of refinancing an existing affiliate loan and advancing general corporate liquidity, while investors reacted to both the discounted pricing of the notes and the near-term earnings miss.


Contextual note - The article presents the terms and expected uses of proceeds as disclosed by the company and the reported quarter results. It does not provide projections or additional commentary beyond those disclosures.

Risks

  • Potential dilution - The conversion terms create the possibility of additional shares outstanding if noteholders convert, which can affect existing equity holders and is relevant to capital markets and investor returns.
  • Debt servicing and timing - The notes carry 6.75% interest and mature in 2034, with certain repurchase and non-redemption provisions; this creates medium- to long-term obligations for the company and is pertinent to credit and financing risk.
  • Earnings uncertainty - The company missed the EPS consensus by $0.01 in the quarter even as revenue exceeded estimates, indicating mixed near-term operating results that may influence investor sentiment in the biotech and small-cap sectors.

More from Stock Markets

Pennsylvania Seeks Court Order to Stop Character.AI Chatbots from Claiming to Be Doctors May 5, 2026 Anthropic Accelerates Push into Financial Services with 10 Specialized AI Agents May 5, 2026 Sonos Shares Drop After Bose Launches New Lifestyle Speaker Line May 5, 2026 DHL Teamsters Ratify Four-Year Deal Delivering 20% Pay Raise and Job Protections May 5, 2026 Figure rolls out SEC-registered yield-bearing dollar token on Stellar May 5, 2026